147 related articles for article (PubMed ID: 8336195)
41. [A case of malignant pleural mesothelioma and its sensitivity tests for anti-cancer drugs].
Asakura S; Matsui T; Tatsumi A; Fujio A; Kitano M; Kobashi Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1988 Jul; 26(7):695-9. PubMed ID: 3149385
[No Abstract] [Full Text] [Related]
42. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel JC; Finkelstein DM; Ettinger DS; Creech RH; Mason BA; Joss RA; Vogl S
J Clin Oncol; 1986 Jan; 4(1):14-22. PubMed ID: 3510278
[TBL] [Abstract][Full Text] [Related]
43. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
45. [A case of remission in diffuse pleural mesothelioma induced by anticancer chemotherapy with cisplatin and adriamycin].
Kinoshita S; Yamashita T; Yagi M; Bando H; Tsubura E; Sano T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1872-6. PubMed ID: 4041164
[TBL] [Abstract][Full Text] [Related]
46. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin.
Arrieta O; Medina LA; Estrada-Lobato E; Ramírez-Tirado LA; Mendoza-García VO; de la Garza-Salazar J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):211-5. PubMed ID: 24817602
[TBL] [Abstract][Full Text] [Related]
47. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; Rodinò C; Soldani M
J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
[TBL] [Abstract][Full Text] [Related]
48. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
[TBL] [Abstract][Full Text] [Related]
49. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
50. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
51. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
Fennell DA; Steele JP; Shamash J; Evans MT; Wells P; Sheaff MT; Rudd RM; Stebbing J
Cancer; 2007 Jan; 109(1):93-9. PubMed ID: 17146783
[TBL] [Abstract][Full Text] [Related]
53. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
Am J Clin Oncol; 2001 Apr; 24(2):143-7. PubMed ID: 11319288
[TBL] [Abstract][Full Text] [Related]
54. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
56. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F
Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014
[TBL] [Abstract][Full Text] [Related]
57. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
[TBL] [Abstract][Full Text] [Related]
59. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.
Langer CJ; Rosenblum N; Hogan M; Nash S; Bagchi P; LaCreta FP; Catalano R; Comis RL; O'Dwyer PJ
Cancer Chemother Pharmacol; 1993; 32(3):204-8. PubMed ID: 8500225
[TBL] [Abstract][Full Text] [Related]
60. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.
Muers MF; Rudd RM; O'Brien ME; Qian W; Hodson A; Parmar MK; Girling DJ;
Thorax; 2004 Feb; 59(2):144-8. PubMed ID: 14760156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
